3-Oxotetradecanal

3-Oxotetradecanal

SCHEMBL1301744

CCCCCCCCCCCC(=O)CC=O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MAPT P10636 1/20 0.56
CES2 O00748 3/20 0.52
CES1 P23141 3/20 0.52
GPR84 Q9NQS5 7/20 0.50
PPARG P37231 7/20 0.50
PPARD Q03181 7/20 0.50
PPARA Q07869 7/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
PTPN1 P18031 3/20 0.50
ALDH1A1 P00352 2/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
FABP4 P15090 2/20 0.50
FAAH O00519 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50
MEN1 O00255 1/20 0.50
ESR1 P03372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3992015 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
Houttuynin SCHEMBL1144900 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
SCHEMBL3987687 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
SCHEMBL3992626 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
SCHEMBL3986013 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
SCHEMBL3993688 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
SCHEMBL3990464 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
3-Oxodecanal SCHEMBL3646476 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
SCHEMBL3877076 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84
SCHEMBL3987323 1.00 KMT2A (0.56) KMT2AMAPTCES2CES1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680020-A1 COMPOSITIONS INCLUDING ALDEHYDES WITH IMPROVED RELEASE RATE AND DEGRADATION PROPERTIES FMC Agricultural Solutions A/S (DK) 2026-01-21 EP claimed
WO-2024189207-A1 COMPOSITIONS INCLUDING ALDEHYDES WITH IMPROVED RELEASE RATE AND DEGRADATION PROPERTIES FMC Agricultural Solutions A/S (DK) 2024-09-19 WO claimed
CN-107960589-A A kind of antibacterial additives chitosan oligosaccharide aldehyde schiff bases and application 湖南晶天科技实业有限公司 2018-04-27 CN claimed
CN-107960532-A A kind of feed addictive and a kind of feed 湖南晶天科技实业有限公司 2018-04-27 CN claimed
CN-102153492-B Medicine of anti-infectious disease and its production and use LIU LI (CN) 2016-01-13 CN claimed
CN-102964276-A Preparation method of sodium new houttuyfonate KAMP PHARMACEUTICALS CO LTD 2013-03-13 CN claimed
US-7371779-B2 Synergistic compositions of N-acylhomoserine lactones and 4-quinolones THE SECRETARY OF STATE FOR DEFENSE SCIENCE AND TECHNOLOGY (GB) 2008-05-13 US claimed
US-20050014751-A1 Use of n-acyl homoserine lactones for the treatment of insulitis THE UNIVERSITY OF NOTTINGHAM (GB) 2005-01-20 US claimed
US-20040259942-A1 Modulation of stat activity SHAW PETER (GB) 2004-12-23 US claimed
EP-1404315-B1 SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES UNIV NOTTINGHAM (GB) 2004-11-03 EP claimed
EP-1404315-A1 SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES THE UNIVERSITY OF NOTTINGHAM (GB) 2004-04-07 EP claimed
CN-1454591-A Encapsulated preparation of sodium decanoy acetaldehyde LI HONGJIE (CN) 2003-11-12 CN claimed
US-20030171371-A1 Immunosuppressant n-acyles homoserine lactones THE UNIVERSITY OF NOTTINGHAM (GB) 2003-09-11 US claimed
WO-2003026641-A2 MODULATION OF STAT ACTIVITY UNIVERSITY OF NOTTINGHAM (GB) 2003-04-03 WO claimed
WO-2003022828-A1 USE OF N-ACYL HOMOSERINE LACTONES FOR THE TREATMENT OF INSULITIS THE UNIVERSITY OF NOTTINGHAM (GB) 2003-03-20 WO claimed
WO-2003004017-A1 SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES THE UNIVERSITY OF NOTTINGHAM (GB) 2003-01-16 WO claimed
EP-1268459-A1 IMMUNOSUPPRESSANT N-ACYL HOMOSERINE LACTONES THE UNIVERSITY OF NOTTINGHAM (GB) 2003-01-02 EP claimed
WO-2001074801-A1 IMMUNOSUPPRESSANT N-ACYLES HOMOSERINE LACTONES UNIVERSITY OF NOTTINGHAM (GB) 2001-10-11 WO claimed
WO-1999027786-A1 CONTROL OF BIOFILM FORMATION THE UNIVERSITY OF NOTTINGHAM (GB) 1999-06-10 WO claimed
EP-0466838-B1 NOVEL LIPID A DERIVATIVES AND USES THEREFOR WISCONSIN ALUMNI RES FOUND (US) 1998-04-01 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259942-A1 Modulation of stat activity STAT3, STAT1, STAT4 KMT2A 2237/4885MAPT 4800/4885CES2 3508/4885
US-20050014751-A1 Use of n-acyl homoserine lactones for the treatment of insulitis HPGDS, CD14, IFNG KMT2A 4475/4885MAPT 4663/4885CES2 3838/4885
US-20030171371-A1 Immunosuppressant n-acyles homoserine lactones MSR1, IL4, SRR KMT2A 3356/4885MAPT 4833/4885CES2 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.